[ECYT] Endocyte, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 2.72 Change: 0.1 (3.82%)
Ext. hours: Change: 0 (0%)

chart ECYT

Refresh chart

Strongest Trends Summary For ECYT

ECYT is in the long-term up 1409% in 3 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its proprietary technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is primarily developing vintafolide, a SMDC that targets the platinum-resistant ovarian cancer, non-small cell lung cancer, triple negative breast cancer, and carboplatin/paclitaxel combination; and etarfolatide, a proprietary companion imaging agent for vintafolide. The company is also developing product candidates for colorectal, prostate, kidney, endometrial, solid tumors, and other cancers, as well as for chronic inflammatory disorders. The company has a collaboration agreement with Merck Sharp & Dohme Research GmbH for the development and commercialization of vintafolide. Endocyte, Inc. was founded in 1995 and is headquartered in West Lafayette, Indiana.

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -99.97% Sales Growth - Q/Q0% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-1.12% ROE-1.16% ROI
Current Ratio29.35 Quick Ratio Long Term Debt/Equity Debt Ratio0.03
Gross Margin Operating Margin-5.12% Net Profit Margin-4.27% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities240 K Cash From Investing Activities-6.5 M Cash From Operating Activities-10.04 M Gross Profit
Net Profit-10.87 M Operating Profit-10.96 M Total Assets202.61 M Total Current Assets162.19 M
Total Current Liabilities5.53 M Total Debt Total Liabilities6.42 M Total Revenue10 K
Technical Data
High 52 week23.85 Low 52 week2.96 Last close23.6 Last change0%
RSI54.55 Average true range0.16 Beta1.33 Volume103.16 K
Simple moving average 20 days-0.07% Simple moving average 50 days16.09% Simple moving average 200 days62.95%
Performance Data
Performance Week-0.04% Performance Month0.9% Performance Quart28.47% Performance Half77.04%
Performance Year389.63% Performance Year-to-date451.4% Volatility daily0.51% Volatility weekly1.14%
Volatility monthly2.33% Volatility yearly8.08% Relative Volume217.05% Average Volume2.92 M
New High New Low

News

2019-01-07 18:24:00 | Novartis CEO talks chasing cures over profitable treatments, says they will 'ultimately' be valued

2019-01-07 18:24:00 | Novartis CEO talks chasing cures over profitable treatments, says they will 'ultimately' be valued

2018-12-20 09:25:00 | Endocyte Stockholders Approve Merger Agreement with Novartis AG

2018-12-13 11:42:24 | Why Arrowhead Pharmaceuticals Stock Rose Over 10% Yesterday

2018-12-08 05:29:48 | Do Hedge Funds Love Endocyte, Inc. ECYT?

2018-11-26 11:33:35 | Endocyte Stock Has Seen a Solid Hike in 2018

2018-11-16 18:05:00 | Monteverde & Associates PC Files Class Action Lawsuit On Behalf Of Shareholders Of Endocyte, Inc. In The U.S. District Court For The Southern District Of New York

2018-11-09 16:50:09 | A Closer Look at Insys Therapeutics’ Performance Year-to-Date

2018-11-09 08:55:00 | Recent Analysis Shows Audentes Therapeutics, Endocyte, Bluerock Residential Growth REIT, Air Products and Chemicals, BWX Technologies, and Modine Manufacturing Market Influences — Renewed Outlook, Key Drivers of Growth

2018-11-07 18:50:11 | Endocyte ECYT Reports Q3 Loss, Tops Revenue Estimates

2018-11-07 17:44:13 | Endocyte: 3Q Earnings Snapshot

2018-11-07 16:01:00 | Endocyte Provides Third Quarter 2018 Financial Results and Operational Update

2018-11-02 05:08:13 | Bayer CEO backs group's diversified structure

2018-11-01 23:53:00 | SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Endocyte, Inc. - ECYT

2018-10-26 09:51:01 | Zacks.com featured highlights include: Lamb Weston, Dollar General, Endocyte and CONSOL

2018-10-19 10:41:02 | Can The Uptrend Continue for Endocyte ECYT?

2018-10-19 08:28:26 | The Daily Biotech Pulse: Novartis Positive Liver Drug Trials, Krytstal Prices Offering, LogicBio To Debut

2018-10-19 08:00:00 | Today’s Research Reports on Stocks to Watch: Proteostasis Therapeutics and Endocyte

2018-10-18 19:46:16 | [$$] Novartis to Buy Cancer-Drug Maker Endocyte for $2.1 Billion

2018-10-18 16:11:00 | Stocks plunge, Dow falls 327 points

2018-10-18 14:58:15 | Endocyte's $2.1 Billion Deal Rewards Investors Who Stuck It Out

2018-10-18 13:30:45 | Novartis to Buy Biopharmaceutical Company Endocyte for $2.1 Billion

2018-10-18 13:28:00 | This tiny biotech spun a quick $2 billion from $12 million

2018-10-18 11:06:26 | [$$] These Guys Should Start a Hedge Fund

2018-10-18 11:06:15 | Novartis buying cancer drug maker Endocyte for $2.1B

2018-10-18 09:41:55 | Novartis Gets Key Therapy -- For Almost 200 Times Its Last Price

2018-10-18 09:35:00 | Why Endocyte, Inc. Stock Is Soaring Today

2018-10-18 09:16:00 | Novartis Secures Prostate Cancer Treatment With Endocyte Deal

2018-10-18 09:06:46 | Novartis To Buy Endocyte In $2.1B Deal

2018-10-18 08:48:53 | Exclusive: Walmart set to deliver more products with high-tech help

2018-10-18 07:56:42 | The Daily Biotech Pulse: Novartis Buys Endocyte, Proteostasis Positive Cystic Fibrosis Trial, 2 IPOs

2018-10-18 07:54:00 | Stocks making the biggest move premarket: TRV, BX, BK, DHR, TXT, PM & more

2018-10-18 07:24:00 | Endocyte stock pops 50% on $2.1 bln Novartis acquisition

2018-10-18 07:17:00 | Facebook, Fed Minutes, AmEx, PayPal and Endocyte - 5 Things You Must Know

2018-10-18 06:24:11 | [$$] European Equities Market Talk Roundup

2018-10-18 05:06:01 | Novartis pushes deeper into nuclear medicine with $2.1 billion deal

2018-10-18 05:00:46 | Novartis pushes deeper into nuclear medicine with $2.1 bln deal

2018-10-18 03:39:12 | Endocyte Enters Into Agreement to be Acquired by Novartis for $24/Share

2018-10-18 02:58:47 | Novartis to buy cancer drugmaker Endocyte for $2.1 billion in cash

2018-10-18 02:28:10 | Novartis to buy cancer drugmaker Endocyte for $2.1 bln in cash

2018-10-18 01:50:54 | Novartis raises 2018 sales outlook as Entresto, Cosentyx accelerate

2018-10-10 08:35:00 | New Research Coverage Highlights Endocyte, Power Integrations, Caterpillar, PROS, Ingevity, and SunCoke Energy — Consolidated Revenues, Company Growth, and Expectations for 2018

2018-10-09 08:14:17 | Do Institutions Own Shares In Endocyte Inc NASDAQ:ECYT?

2018-10-05 09:00:57 | What Seattle Genetics’ Valuation Trend Indicates

2018-10-04 13:25:47 | Seattle Genetics: Impact of the Cascadian Acquisition

2018-10-03 12:07:13 | Why Analysts See a Massive Upside in Madrigal Stock

2018-10-03 06:00:00 | Endocyte becomes first Purdue startup to reach $1.5B in value

2018-09-27 08:01:00 | Endocyte to Present at Two Investor Conferences on October 2nd

2018-09-25 10:46:55 | Innovative Oncology Pipeline Is a Key Growth Driver for Endocyte

2018-09-14 16:01:00 | Endocyte Announces Closing of Public Offering of Common Stock